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Abstract
IgE antibodies are key mediators of anti-parasitic immune responses, but their potential for cancer 
treatment via antibody-directed cell-mediated cytotoxicity (ADCC) has been little studied. 
Recently, tumor antigen-specific IgEs were reported to restrict cancer cell growth by engaging 
high-affinity Fc receptors on monocytes and macrophages, however, the underlying therapeutic 
mechanisms were undefined and in vivo proof-of-concept was limited. Here, an 
immunocompetent rat model was designed to recapitulate the human IgE-Fcε receptor system for 
cancer studies. We also generated rat IgE and IgG monoclonal antibodies specific for the folate 
receptor (FRα), which is expressed widely on human ovarian tumors, along with a syngeneic rat 
tumor model expressing human FRα. Compared with IgG, anti-FRα IgE reduced lung metastases. 
This effect was associated with increased intra-tumoral infiltration by TNFα+ and CD80+ 
macrophages plus elevated TNFα and the macrophage chemoattractant MCP-1 in lung 
bronchoalveolar lavage fluid. Increased levels of TNFα and MCP-1 correlated with IgE-mediated 
tumor cytotoxicity by human monocytes and and with longer patient survival in clinical specimens 
of ovarian cancer. Monocytes responded to IgE but not IgG exposure by upregulating TNFα, 
which in turn induced MCP-1 production by monocytes and tumor cells to promote a monocyte 
chemotactic response. Conversely, blocking TNFα receptor signaling abrogated induction of 
MCP-1, implicating it in the antitumor effects of IgE. Overall, these findings show how anti-tumor 
IgE reprograms monocytes and macrophages in the tumor microenvironment, encouraging the 
clinical use of IgE antibody technology to attack cancer beyond the present exclusive reliance on 
IgG.
Introduction
Engagement of tumor-specific monoclonal antibodies via their Fc receptors contributes 
significantly to the anti-tumor effects of the immune system (1). Focusing effector cells such 
as monocytes/macrophages and natural killer (NK) cells against cancer-associated 
components may contribute to the functions of therapeutic antibodies such as trastuzumab, 
cetuximab and the checkpoint inhibitor ipilimumab (2, 3). Antibody engineering strategies 
to optimize antibody-effector cell interactions and to direct these cells against tumors, may 
therefore improve therapeutic efficacy (4, 5).
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One strategy to influence these interactions is the exploration of changes to the structure of 
antibody Fc regions. The IgE immunoglobulin class is characterized by high affinity for 
cognate interaction with Fcε receptors (100-10,000 times higher than that of IgG for FcγR) 
on distinct, often tumor-resident, effector cells such as monocytes/macrophages (6, 7). 
Although IgE antibodies play pathogenic roles in allergic inflammation by triggering mast 
cell degranulation and promoting eosinophil inflammation, they also contribute to the host 
immune defense against parasitic infections. The potential of IgE to induce inflammatory 
responses at tumor sites may be harnessed through IgE receptor-expressing effector cells 
such as monocytes and macrophages in tumors. Strategies to implement this approach 
include recombinant tumor-associated antigen (TAA)-specific IgEs, and active 
immunotherapy triggering adaptive IgE responses against cancer (8–12).
Folate receptor alpha (FRα) is overexpressed by several solid tumors, most significantly by 
epithelial ovarian carcinomas (13), and is a desirable target for TAA-specific IgE due to 
overexpression in tumors, and no/low expression and restricted distribution in normal 
tissues. Additionally, evidence of negative associations between allergies and reduced risk of 
gynaecological malignancies is reported (14), while little is known about IgE immunity 
against ovarian carcinoma antigens in patients (15). The chimeric (mouse V/human C) IgE 
antibody hMOv18 IgE, specific for FRα (16, 17), effected superior tumor cell cytotoxicity 
and improved survival compared with IgG1 of equivalent specificity (18–21). Potential roles 
of monocytes/macrophages were suggested by loss of IgE-conferred survival advantage 
following monocyte depletion of human peripheral blood mononuclear cells (PBMCs) 
introduced with hMOv18 IgE (20). Monocyte-mediated tumor killing was demonstrated 
through both known IgE receptors: antibody-dependent cell-mediated cytotoxicity (ADCC) 
via the high affinity FcεRI, and phagocytosis (ADCP) via the low affinity FcεRII (CD23). 
Since inflammatory infiltrates of many tumors contain macrophages, re-polarizing these 
against cancer may constitute an important rationale for developing IgE cancer 
immunotherapy (22). To-date however, the capacity of IgE to recruit macrophages against 
cancer in an immunocompetent tumor-bearing setting has not been demonstrated and the 
mechanisms by which IgE may activate these cells against cancer remain unclear. IgE can 
rapidly mediate parasite neutralization by FcεR-expressing cells including human 
macrophages (23, 24). Although TNFα, IL-10 and nitric oxide (NO) have been individually 
reported in these processes (23–25), the mechanisms engendered through cross-talk between 
immune cells, IgE antibodies and target cell antigens, including parasite or tumor antigens, 
have not been elucidated.
Lack of cross-reactivity of human IgE with murine FcεRs and absence of trimeric FcεRI on 
murine monocytes/macrophages, eosinophils and other subsets have provided challenges for 
the design of immunologically-relevant models with which to study IgE class antibody 
functions. Previous immunodeficient mouse models, some reconstituted with human 
immune cells to provide IgE effector cells, were limited by short lifespans of human effector 
cells and incomplete representation of human immunity. Additionally, certain human 
effector cell-secreted cytokines may not interact with the murine immune system.
We investigated whether MOv18 IgE can inhibit tumor progression by recruiting and 
polarizing macrophages. We constructed a syngeneic rat model of FRα-expressing 
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adenocarcinoma designed to better recapitulate the human IgE-Fcε receptor system and the 
patient setting. In this model, immune cells are found in their natural anatomical locations, 
immune cell FcεRI expression and distribution in rats mirrors that of humans, and rat 
effector cells (e.g. monocytes/macrophages) express trimeric FcεRI (αγ2) (26). We 
generated anti-FRα IgE and IgG with rat Fc sequences (rMOv18 IgE/IgG2b) to examine 
alongside antibodies with human Fc (hMOv18 IgE/IgG1). We assessed antibody efficacy 
and IgE-mediated tissue macrophage migration and activation in vivo, and TNFα and 
MCP-1 in tumor environments. We evaluated relevance in the human system and dissected 
the conditions that promote TNFα and MCP-1, by IgE-mediated human monocyte 
activation. Our findings support the superior therapeutic efficacy of IgE over IgG, and 
identify a previously-unappreciated tumor antigen-specific IgE-potentiated axis that 
promotes effector cell polarization and recruitment towards tumor cells.
Materials and Methods
Human Samples and Ethics
Blood and tumor specimens were collected from 6 ovarian carcinoma patients 
(Supplementary Table S1) and blood drawn from 13 healthy volunteers (Supplementary 
Table S2), with informed written consent, in accordance with the Helsinki Declaration. 
Study design was approved by the Guy’s Research Ethics Committee, Guy’s and St. 
Thomas’ NHS Foundation Trust.
Cell Lines
The CC531tFR cell line, originally derived from a 1,2 dimethyhydrazine (DMH)-induced 
colon adenocarcinoma of a WAG-Rij rat (27) (Cell Lines Service), was transfected to 
express human FRα as previously-described, and selected on the basis of Geneticin 
resistance (S. Canevari, M. Colnaghi, Instituto Nazionale Tumori, Milan) (28, 29). IGROV1 
human ovarian carcinoma cells naturally over-express human FRα (18, 30). A375 (human 
metastatic melanoma; CRL-11147), SKOV3 (human epithelial ovarian carcinoma, HTB-77), 
TOV21G (human ovarian clear cell carcinoma, CRL-11730), SKBR3 (human breast 
carcinoma HTB-30), U937 (human monocytic CRL-1593.2), and THP-1 (human monocytic; 
TIB 202) cells were from ATCC. FreeStyleTM 293-F cells (R790-07) were from Invitrogen 
(Supplementary Materials and Methods). Cell lines from ATCC were authenticated by short 
tandem repeat profiling. Routine Mycoplasma testing was performed by PCR regularly on 
all cell lines.
Production of anti-FRα antibodies with human and rat Fc regions
Chimeric mouse/human antibodies MOv18 IgE and IgG1 recognizing human FRα were 
engineered as before (18). Chimeric mouse/rat MOv18 IgE and IgG2b antibodies were 
designed with rat constant and mouse variable domains specific for human FRα 
(Supplementary Materials and Methods).
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Tumor cell cytotoxicity and phagocytosis (ADCC/ADCP) assays
Antibody-dependent cell-mediated killing of FRα-expressing tumor cells was quantified by 
adapting a previously-described flow cytometric method (Supplementary Materials and 
Methods).
Assessments of antibodies in vivo
Immunocompetent syngeneic WAG rat model of FRα-expressing lung 
metastases—Female Wistar Albino Glaxo (WAG/RijCrl) rats (Charles River) were 
maintained and handled in accordance with the Institutional Committees on Animal Welfare 
of the UK Home Office (The Home Office Animals Scientific Procedures Act, 1986). Rats 
were injected i.v. with 4x106 CC531tFR tumor cells and subsequently treated with MOv18 
antibodies (days 1 and 14 or 1, 7, 14 and 21). Lung tumor burden was determined 26 days 
following CC531tFR inoculation by: mean number of surface-visible metastases/cm2; and % 
tumor occupancy [total white surface area (mm2) / total lung (black + white) surface area 
(mm2)].
Assessment of hMOv18 IgE in immune deficient mouse models—Patient-derived 
intraperitoneal (i.p.) human ovarian carcinoma xenografts in female nu/nu mice were 
previously described (19). Subcutaneous IGROV1 tumors were established in C.B-17 scid/
scid (SCID) mice as before (18) (Supplementary Materials and Methods).
Isolation of rat effector cells from peripheral blood and lungs
Rat primary monocytes were prepared from rat peripheral blood leukocytes (PBL) by flow 
cytometry cell sorting using a PE-conjugated antibody against CD172 (BD Biosciences) 
(Supplementary Materials and Methods).
Flow cytometric evaluations of freshly-isolated tumor-infiltrating macrophages
Phenotypic analysis of tumor-infiltrating macrophages from single cell suspensions of 
tumor-bearing rat lungs was performed with directly-labeled monoclonal antibodies 
(Supplementary Materials and Methods).
Criteria for evaluating immune cell infiltration of tumors
H&E-stained sections were used to determine the tumor immune cellular infiltrate as a 
proportion of total tumor areas (Supplementary Materials and Methods). The percentage of 
tumor occupied by immune cells in each section was derived as follows: % immune cell 
occupancy = total area occupied by immune cells/total tumor area (Supplementary Fig. 
S1A).
Evaluations of macrophage infiltration into tumors
Sections double-stained for FRα (AF488, green) and CD68 (AF555, red) were used to 
determine ratios of within-tumor:peripheral CD68+ cells/mm2. CD68+ cells and the area 
covered by tumor (defined by tissue morphology, density of DAPI staining and FRα 
staining; Supplementary Fig. S1B) and periphery was calculated. (Supplementary Materials 
and Methods).
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Quantitative real-time-PCR analysis of TNFα and MCP-1 expression by tumor cells and 
monocytes
Cells harvested from ADCC and ex vivo stimulation assays were studied for MCP-1 and 
TNFα relative gene expression. Cells from ADCC assays were CD89-PE- and FRα-FITC-
labeled and sorted using a FACSAria II Cell Sorter (BD Biosciences). Sorted cells and cells 
from ex vivo stimulation experiments (Supplementary Materials and Methods) were re-
suspended in RLT buffer for RNA isolation by RNeasy Kit (Qiagen).
Chemotaxis assay
To analyze the chemotactic properties of MCP-1 on THP-1 cells and human primary 
monocytes, a chemotaxis assay was performed using Transwell® plates with a 
polycarbonate membrane insert and 5μm pore size (Costar®) (Supplementary Materials and 
Methods).
Statistical methods and analyses of publically-available databases
All statistical analyses (Supplementary Materials and Methods) were performed using 
GraphPad™ Prism software (version 5.03, GraphPad™). P values are represented as 
follows: *=P<0.05, **=P<0.01, ***=P<0.001, ****=P<0.0001. Error bars represent SD and 
SEM in in vitro figures, and in in vivo figures and histological analyses, respectively. 
Clinical associations of tumor gene expression were assessed using publicly-available data 
(31), in Kaplan-Meier Plotter (http:/kmplot.com/analysis/) (Supplementary Materials and 
Methods).
Results
Rat and human IgE and IgG display comparable in vitro properties
We generated surrogate rMOv18 IgE and IgG2b antibodies (equivalent to mouse IgG2a/b 
and human IgG1, based on their complement-fixing and ADCC functions) recognizing 
human FRα in order to construct a syngeneic rat model system. Human FRα-expressing 
WAG rat syngeneic adenocarcinoma CC531tFR cells served as targets. Rat peripheral blood 
monocytes (CD172+) expressed FcεRI and bound rMOv18 IgE (Figs. 1A-B). rMOv18 IgE 
bound to rat FcεRI (αβγ2)-expressing rat RBL-2H3 mast cells. rMOv18 IgG2b bound 
primary rat monocytes (expressing FcγRI), and RBL-2H3 cells (expressing low levels of 
rFcγRII/FcγRIII). Rat IgE and IgG2b bound to CC531tFR but not to FRα-negative A375 
melanoma cells (Fig. 1B).
Rat primary monocytes activated ex vivo with rMOv18 IgE, and rMOv18 IgG2b induced 
significant CC531tFR cell death compared with isotype control antibodies and equivalent to 
levels of IGROV1 ovarian tumor cell death triggered by human antibodies (Fig. 1C). 
Furthermore, monocytic cells stimulated with IL-4 to express the low affinity IgE receptor 
CD23/FcεRII, and primed with rMOv18 IgE, triggered significant CC531tFR death by 
ADCP over control antibody, equivalent to levels of ADCP triggered by hMOv18 IgE (Fig. 
1D).
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This suggests that rMOv18 antibodies are functionally analogous to their human 
counterparts, at least with regard to binding FcεR+ and FRα+ cells, and their potentiation of 
particular effector functions.
Anti-tumor activities of rat MOv18 IgE and IgG2b in vivo
We next examined the in vivo functions of rMOv18 IgE and IgG2b in an immunocompetent 
rat model of FRα+ CC531tFR lung metastases, designed to better recapitulate the spectrum 
and functions of human IgE effector cells and the patient setting (Supplementary Fig. S2).
Immunofluorescent staining confirmed in situ FRα+ CC531tFR metastases (Fig. 2A). Dose-
dependent inhibition of tumors between 5mg/kg, 10mg/kg and 50mg/kg doses (% tumor 
occupancy of lungs) was observed with rMOv18 IgE (biweekly) (Fig. 2B). Lung metastases 
and tumor occupancy were significantly lower with rMOv18 IgE compared with rMOv18 
IgG2b (P<0.0001) or PBS (P<0.0001) (Figs. 2C-E) at 10mg/kg doses. IgE and IgG2b 
significantly reduced lung metastases at 5mg/kg compared with PBS (P<0.0001). Given the 
longer serum half-life of IgG (14-25 days) compared with IgE (1-2 days) (32), we 
investigated whether dosing frequency could influence efficacy. rMOv18 IgE dosed weekly 
induced significantly-reduced tumor occupancy at doses as low as 1mg/kg compared with 
PBS (P<0.0001), with a dose-dependent response between 3mg/kg, 10mg/kg (P=0.0002) 
and 50mg/kg (P<0.001) (Fig. 2F). Weekly 3mg/kg rMOv18 IgE afforded significantly 
(P=0.04) superior tumor growth restriction compared with IgG2b (Fig. 2G).
Therefore, rMOv18 IgE and IgG2b were functionally active in vivo. Rat MOv18 IgE at 
3mg/kg weekly and 10mg/kg biweekly doses effected superior tumor growth restriction 
compared with IgG2b.
MOv18 IgE treatment is associated with rat macrophage infiltration into tumors
We next investigated spontaneous, endogenous macrophage infiltration into tumors in 
immunocompetent rats. Histological evaluation of rat lungs showed reduced tumor islet 
density and increased glandular organization in rMOv18 IgE- compared with rMOv18 
IgG2b-treated cohorts (Fig. 3A). Tumor areas occupied by immune and stromal cell 
infiltration were significantly greater with rMOv18 IgE compared to PBS (P<0.0001) (Fig. 
3B). We observed superior rat macrophage infiltration into tumors of rMOv18 IgE-treated 
rats. CD68+ macrophage clusters (red) surrounded sparse FRα+ (green) tumor islets. 
Macrophage density within tumor islets was higher in rMOv18 IgE- and rMOv18 IgG2b-
treated rats compared with PBS (P=0.007) (Fig. 3C). CD68+ cell ratios within tumor 
islets:tumor periphery were significantly higher with rMOv18 IgE (rMOv18 IgG2b, P=0.03; 
PBS, P=0.003) (Fig. 3C, Supplementary Fig. S1). Additionally the intensity of macrophage 
infiltration correlated inversely with tumor occupancy in animals treated with rMOv18 IgE, 
and rMOv18 IgG2b but not PBS (Fig. 3D). Analyses of patient-derived ovarian carcinoma 
xenografts, where hMOv18 IgE introduced with human PBMCs prolonged survival of 
tumor-challenged mice compared to controls, showed that human CD68+ macrophage 
infiltration into tumors correlated with prolonged survival of hMOv18 IgE-treated mice 
(r=0.67, P=0.009) (Fig. 3E) (19). Furthermore, in a subcutaneous IGROV1 human ovarian 
cancer xenograft in immunodeficient mice, significant tumor growth was observed in mice 
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given PBS (P=0.0054), hMOv18 IgE alone (P=0.049) or human monocyte-enriched PBMCs 
(P=0.0014), but tumor growth was restricted in mice given hMOv18 IgE plus monocyte-
enriched cells (Fig. 3F). These findings suggest that the anti-tumor effects of MOv18 IgE in 
vivo, at least partly reflect immune effector functions of the antibody and enhanced 
macrophage influx into the tumor mass.
Macrophage polarization and elevated TNFα, MCP-1 and IL-10 in lungs of IgE-treated rats
Since antibody treatments were associated with enhanced macrophage infiltration into 
tumors, we investigated whether IgE was associated with polarization or maturation of 
tissue-resident macrophages. Consistent with immunohistochemical evaluations (Fig. 3), the 
mean percentages of freshly-isolated lung CD68+ macrophages within the total CD45+ 
leukocyte populations (Supplementary Fig. S3) were elevated in rats treated with rMOv18 
IgE compared with IgG2b and PBS (Fig. 4A). Macrophages from rMOv18 IgE-treated rats 
demonstrated enhanced expression of the co-stimulatory molecule CD80, compared with 
those from rMOv18 IgG2b- or PBS-treated animals (P=0.01). No differences in the 
alternatively activated (M2) scavenger receptor CD163 (33) expression were found between 
treatment groups (Figs. 4B-C).
A higher proportion of CD68+ macrophages from rMOv18 IgE-treated rats expressed 
intracellular TNFα, compared with rMOv18 IgG2b- and PBS-treated cohorts (P=0.04) 
(Figs. 4B-C). Additionally, a higher proportion of these cells also expressed intracellular 
IL-10 with rMOv18 IgE treatment, compared with rMOv18 IgG2b- (P=0.04) and PBS-
treated cohorts (P=0.04). A proportion of macrophages from rMOv18 IgE-treated rats 
simultaneously expressed TNFα and IL-10 (Fig. 4D). In conjunction (Figs. 4E-F), we found 
significantly elevated TNFα, MCP-1 and IL-10 secreted in bronchoalveolar lavage (BAL) 
fluids of IgE-treated rats compared with IgG (IL-10, P=0.044; TNFα, P=0.017; MCP-1, 
P<0.001). Levels of IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, and IL-12 did not 
differ significantly between treatment groups (Fig. 4E).
These data demonstrate TNFα-expressing mature macrophage subsets in rMOv18 IgE-
treated rat lungs, along with a significantly-elevated secreted TNFα/MCP-1/IL-10 IgE-
associated BAL profile.
Cross-linking of cell surface-bound IgE triggers elevated TNFα by monocytes, and TNFα 
stimulates MCP-1 by monocytes and tumor cells
We sought to determine whether rMOv18 IgE treatment-associated macrophage activation is 
relevant in a human setting, and gain insights into how tumor antigen-specific IgE may 
trigger effector cell activation. Cross-linking of IgE antibodies of different antigen 
specificities (anti-FRα MOv18, anti-hapten NIP IgE, anti-HER2 against the breast cancer 
tumor antigen HER2/neu and CSPG4 IgE, recognizing the melanoma tumor associated 
antigen Chondroitin Sulfate Proteoglycan 4 (34, 35)) on monocytes with polyclonal anti-IgE 
antibody (to mimic engagement by TAA-expressing tumor cells) significantly increased 
production of mRNA encoding TNFα by human monocytes, compared to IgE alone. 
Crosslinking of equivalent IgG1s did not trigger TNFα, nor did cross-linking of IgEs on 
human ovarian IGROV1 tumor cells (Fig. 5A).
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We then investigated whether IgE Fc-mediated TNFα upregulation can promote MCP-1 
secretion and therefore, putatively, monocyte mobilization. TNFα stimulation of human 
monocytic U937 cells and primary human monocytes triggered elevated MCP-1 mRNA 
expression compared with unstimulated cells (Fig. 5B left; P<0.0001), along with elevated 
MCP-1 protein secretion compared with unstimulated cells (Fig. 5B right; U937 P=0.002; 
primary human monocytes P=0.0116).
Stimulation of ovarian IGROV1, SKOV3 and TOV21G, breast SKBR3 and melanoma A375 
cancer cells with TNFα induced significantly-elevated MCP-1 mRNA expression and 
secretion compared with unstimulated cells (Fig. 5C). Furthermore, MCP-1 stimulation 
could effect human monocyte chemotaxis (human primary monocytes, THP-1 monocytes) in 
a concentration-dependent manner (Fig. 5D).
Therefore, TNFα upregulation, triggered by cross-linking of receptor-bound IgE, but not 
IgG, on the surface of monocytes, may induce MCP-1 production by human monocytes and 
a range of tumor cell types, putatively promoting further monocyte chemotaxis and potential 
accumulation in tumors. These data suggest that IgE-mediated monocyte activation and 
TNFα upregulation may be relevant in the human setting.
TNFα and MCP-1 are involved in antigen-specific IgE effector functions and may be 
associated with better patient survival
We investigated whether TNFα/MCP-1 upregulation could be triggered by specific tumor 
antigen recognition and tumor cell cytotoxicity by IgE in vitro. Human monocytes with 
hMOv18 IgE induced significantly-elevated IGROV1 cell ADCC compared with non-
specific NIP IgE controls (Fig. 6A). hMOv18 IgE treatment was associated with 
significantly-elevated expression (relative to control IgE) of the same mediators found in 
lung extracts of IgE-treated rats in vivo (MCP-1, P=0.002; TNFα, P=0.019; IL-10, 
P=0.025), confirming their importance in IgE stimulation (Fig. 6B).
In ADCC assays, MCP-1 secretion with hMOv18 IgE was significantly reduced (P=0.004) 
by TNFα receptor-blocking antibodies (Fig. 6C), and tumor-specific hMOv18 IgE, but not 
the non-specific anti-NIP IgE, triggered upregulated MCP-1 mRNA expression by IGROV1 
tumor cells. This effect was abrogated when TNFα signaling was blocked prior to 
stimulation with antibody (P=0.032; Fig. 6D). Therefore, MCP-1 production in the context 
of tumor antigen-specific IgE cytotoxicity is TNFα-dependent.
To gain insights into a potential clinical relevance of the TNFα/MCP-1 axis, we interrogated 
publicly-available ovarian carcinoma gene expression datasets (Fig. 6E). We found 
significant associations of improved 5-year overall survival with elevated levels of our herein 
reported IgE-mediated immune signatures (TNFα/MCP-1, P=0.016; TNFα/MCP-1/IL-10, 
P=0.022). These signatures were still associated with better overall survival alongside the 
macrophage marker CD68 (P=0.04) and with the high- and low-affinity IgE Fc receptors 
(FcεRI, P=0.041; FcεRII/CD23, P=0.035). These findings may suggest that, if enhanced, the 
TNFα/MCP-1 axis may provide a responsive immune signature with protective potential.
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In summary, within tumors, cross-linking of MOv18 IgE on macrophages by FRα-
expressing tumor cells induces macrophage TNFα upregulation. TNFα promotes elevated 
MCP-1 production by both tumor cells and macrophages, putatively acting as a potent 
chemoattractant, drawing macrophages into tumors. Enhanced tumor cell-macrophage 
interactions further stimulate production of TNFα and thus MCP-1, forming a self-
enhancing circuit of macrophage influx into MOv18 IgE-treated tumors (Fig. 6F). This 
supports a link between TNFα stimulation and MCP-1 expression in response to effector 
cell engagement and IgE cytotoxic functions against cancer.
MOv18 IgE triggers anti-tumor ADCC by ovarian cancer patient effector cells
We evaluated the capacity of hMOv18 IgE to trigger anti-tumor ADCC by activating human 
immune effector cells from patients with ovarian carcinomas. PBMCs from patients with 
FRα-positive, FRα–negative and FRα–status unknown ovarian carcinomas (by 
immunohistochemistry, Fig. 7A), together with hMOv18 IgE, induced significantly-elevated 
ovarian carcinoma IGROV1 ADCC compared with non-specific NIP IgE-treated cells (Fig. 
7B), and equivalent to that mediated by healthy volunteer PBMCs (Fig. 7C). Additionally, 
hMOv18 IgE mediated anti-tumor ADCC against 3 FRα-expressing tumor cell lines (human 
ovarian carcinoma IGROV1 and SKOV3, and rat colon adenocarcinoma CC531tFR), but 
minimum ADCC against FRα-dim and FRα-negative cancer cell lines (human ovarian 
carcinoma TOV21G, and human breast carcinoma SKBR3 respectively, Fig. 7D, 
Supplementary Fig. S4). Therefore, IgE-engendered anti-tumor functions are target antigen-
specific, and have potential application with patient immune effector cells and against 
different target-expressing tumor cells.
Discussion
We report the superior anti-tumor efficacy of TAA-specific IgE in an immunocompetent 
syngeneic rat model of cancer, uniquely suitable for the study of IgE anti-tumor effector 
functions. We furthermore describe a previously-unappreciated putative contribution of a 
TNFα/MCP-1 cascade to monocyte and macrophage repolarization and recruitment, 
delineated in the human IgE and human effector and tumor cell functional context.
The functional significance of this IgE-induced TNFα/MCP-1 axis is supported by: a) 
enhanced intra-tumor infiltration by macrophages following IgE treatments; b) a TNFα-
expressing lung macrophage compartment, and elevated TNFα and MCP-1 concentrations 
in BAL from IgE- but not IgG-treated rats; c) macrophage recruitment correlating with 
tumor growth restriction in IgE-treated syngeneic rat and human xenograft mouse models of 
cancer; d) the ability of human IgE to trigger monocytes to upregulate TNFα in a class-
specific manner; e) the induction of MCP-1 production by TNFα in monocytes and tumor 
cells, in turn shown to promote a monocyte chemotactic response, f) the involvement of 
TNFα/MCP-1 in antigen-specific human IgE tumor ADCC, abrogated with TNFα receptor-
specific blockade on monocyte effector cells and, g) publicly-available ovarian carcinoma 
gene expression datasets indicating associations between elevated levels of TNFα/MCP-1 
with better survival. These findings reveal an immune cascade through which TAA-specific 
IgE may focus macrophages towards tumor cells.
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Rat and human MOv18 IgE showed comparable monocyte-mediated tumor cell killing. In 
immunocompetent rats, rMOv18 IgE demonstrated potential to compete favorably with IgG 
in a metastatic setting, and to restrict tumors in highly-vascularized organs like the lung, 
where IgG (based on its long half-life in the circulation) would have a major advantage. Rat 
and human MOv18 IgE treatment-associated macrophage infiltration into tumors correlated 
with tumor growth restriction and better efficacy in the immunocompetent rat and human 
xenograft mouse models. This supports a function of recruiting macrophages towards tumor 
cells associated with IgE therapy in vivo. Stromal macrophages can express matrix-
degrading, matrix–producing and pro-angiogenic factors (36), allowing regulation of stromal 
remodeling and neo-vascularization to support tumors. Conversely, macrophage density 
within tumor islets has been positively associated with patient survival (37, 38), and tumor 
islet-resident macrophages can express IL-1α, IL-1β, IL-6, NOS and TNFα, the latter two 
thought to be involved in target cell–killing mechanisms of macrophages (39, 40). These 
mechanisms may fail to be effectively deployed against tumors, perhaps partly due to 
alternatively-polarized humoral immunity in cancers favoring antibody isotypes that fail to 
activate key effector cells such as macrophages (41–45). Here we show that tissue-resident 
macrophage subsets in IgE-treated cohorts are polarized to express the macrophage 
maturation and co-stimulatory marker CD80, as well as higher levels of pro-inflammatory 
TNFα. TNFα levels were also enhanced in BAL fluids of IgE-treated but not of IgG-treated 
rats. TNFα can also be expressed by activated macrophages known to act as effector cells in 
IgE-mediated parasite control (23–25). Our findings now directly link tumor-immune cell 
interactions engendered by IgE with potentiating TNFα production, re-education and 
recruitment of monocytes and macrophages into tumors. These functions may be further 
explored in future studies that may include effector cell depletion or enrichment with 
different polarized phenotypes. Based on expression of TNFα, but not IL-4 in vitro and in 
vivo in the context of tumor antigen-specific IgE, our findings also suggest that macrophage 
activatory, but most likely not allergic, mechanisms might be employed by TAA-specific IgE 
to restrict the growth of tumor metastases. IL-4 has been shown to be a negative factor in 
IgE/FcεRI cross-presentation by DCs and generation of cytotoxic T lymphocytes (12). It is 
therefore possible that during Th2-type inflammation, IL-4 may prevent a TNFα/MCP-1 
axis-driven macrophage response.
The CC chemokine, M1 macrophage mediator and potent chemoattractant MCP-1 was also 
elevated in BAL fluid of rMOv18 IgE-treated rats. Cross-linking of macrophage-bound IgE 
by densely-expressed antigens on the surface of target cells, more likely to occur in tumor 
lesions, can trigger TNFα, which in turn may stimulate MCP-1. Our findings suggest that 
cross-linking on the monocyte surface by IgE, but not by IgG, may initiate this TNFα 
response. Monocytes and cancer cells respond to TNFα signals by producing MCP-1, 
consistent with increased recruitment of macrophages into tumors following rMOv18 IgE 
treatment. The high affinity of IgE for FcεRs on tissue-resident monocytes and macrophages 
may result in sustained antibody retention, thus favoring cross-linking of IgE by multivalent 
TAAs. This class-specific immune complex formation may potentiate TNFα production in 
tumor microenvironments and subsequent sustained in situ MCP-1 secretion by different cell 
subsets, providing an advantage for IgE immunotherapy against cancer.
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In human IgE, human monocyte and human tumor cell functional studies, TNFα stimulated 
tumor cells to upregulate MCP-1, which can trigger monocyte chemotaxis. We confirmed 
the relevance of both TNFα and MCP-1 in ADCC assays, where cross-linked IgE on the 
surface of human monocytes upregulated TNFα and MCP-1 production. Loss of MCP-1 
production by tumor cells, and significant reduction in IgE-dependent tumor cell 
cytotoxicity when TNFα signaling was blocked, also suggest that MCP-1 upregulation and 
IgE anti-tumor functions require TNFα. We and others also demonstrate that tumor cells can 
be stimulated to produce MCP-1 (46–49). Additionally, potential synergistic effects between 
MCP-1 and IgE-mediated anti-tumor mechanisms were shown with an anti-MUC1 IgE 
antibody co-administered with MCP-1, to MUC1-expressing tumor-bearing hFcεRIα 
transgenic mice (50). Together, our findings thus point to the putative involvement of a 
TNFα/MCP-1 cascade triggered by IgE-mediated cross-talk between effector cells and 
tumor cells, and implicated in tumor cell growth restriction in vitro and in vivo. Conversely, 
we observed elevated levels of IL-10 in rMOv18 IgE-treated rat lungs and in effector cell 
stimulation assays. In vitro infection of human macrophages with Toxoplasma gondii also 
upregulated IL-10, inversely correlating with iNOS and NO generation, and IL-10 was found 
to attenuate IgE-mediated parasite elimination by macrophages (25). IL-10 could therefore 
provide an in vivo mechanism for restricting IgE-induced effector cell activation, and 
requires further study.
In summary, MOv18 IgE-potentiated tumor-restricting effects are superior to those of IgG in 
immunocompetent rats. IgE immune complex formation on monocytes and macrophages, 
initiated through cross-talk with TAA-expressing cancer cells, promotes effector cell 
polarization, activation and recruitment. This process is driven by TAA IgE-dependent 
TNFα and MCP-1 upregulation. Our findings draw parallels with physiological roles of IgE 
in anti-parasitic immune surveillance but not in allergy. Engineering antibodies with Fc 
regions that confer unique effector cell-polarizing properties against cancer may open a new 
avenue for addressing tumor resistance to immune clearance.
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Figure 1. Rat and human MOv18 antibodies display comparable effector functions.
(A) Anti-rat FcεRI antibody or rMOv18 IgE bind to primary (CD172+) rat monocytes. (B) 
rMOv18 IgE and IgG2b bind to rat primary monocytes, RBL-2H3 rat mast cells, FRα-
expressing rat colon adenocarcinoma CC531tFR cells, and non-FRα-expressing human 
melanoma A375 cells (grey: non-specific isotype control or detection antibody control). (C) 
Quantification of ADCC against FRα-expressing tumor (rat CC531tFR and human ovarian 
carcinoma IGROV1) cells by rat or human MOv18 IgE- or IgG-primed primary monocytes. 
(D) Quantification of ADCC and ADCP against FRα-expressing CC531tFR tumor cells by 
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rat or human MOv18 IgE-primed unstimulated (CD23-) or IL-4 stimulated (CD23+) 
monocytic cells, compared with non-specific antibody treatments or cells alone (n=3).
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Figure 2. Rat MOv18 IgE demonstrates superior tumor growth restriction.
(A) FRα expression in vivo 26 days post-tumor challenge. Representative 
immunofluorescent microscopy images from lungs of tumor-bearing and healthy rats (n=5). 
(B) Percentage (%) tumor occupancy quantified following two biweekly (Q2W) doses of 
PBS (n=20), or 1 (n=3), 3 (n=2), 5 (n=11), 10 (n=11) and 50 (n=2) mg/kg rMOv18 IgE. (C, 
E) Number of metastases/cm2 and % tumor occupancy quantified for PBS-treated rats 
(n=22) and rats treated with rMOv18 IgE (n=11) and IgG2b (n=11) at 10mg/kg and 5mg/kg 
Q2W. (D) Representative images of Indian ink-stained lungs from rMOv18 IgE-, IgG2b- 
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(10mg/kg) and PBS-treated rats. (F) Percentage tumor occupancy quantified following 
weekly doses of rMOv18 IgE (n=10 per dose) or PBS (n=17) (mean of 1-3 independent 
experiments for B, C, E and F). (G) Number of metastases/cm2 and % tumor occupancy 
quantified for rats treated weekly with PBS or with rMOv18 IgE or IgG2b at 3mg/kg.
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Figure 3. MOv18 IgE treatment induces CD68+ macrophage infiltration into tumors.
(A) Paraffin-embedded lung sections from PBS-, rMOv18 IgG-, and rMOv18 IgE-treated 
rats stained with H&E, and (B) percentages of immune cell infiltration into tumor foci 
quantified (demarcation strategy: Supplementary Fig. S1) (5 data points/animal, 5 animals/
group). Magnification 200x. White arrow: glandular tumor islet; black arrow: immune and 
stromal cells. (C) Representative cryosections of lung from PBS-, rMOv18 IgG-, and 
rMOv18 IgE-treated rats co-stained with anti-human FRα (green) and anti-rat CD68 (red) 
antibodies. Intratumoral CD68+ cell density/mm2 (right panel, top) and ratio of 
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tumour:peripheral CD68+ cells (right panel, bottom) were calculated. IgE (n=14), IgG 
(n=17), PBS (n=24). (D) Correlation of within-tumor CD68+ macrophage density with % 
tumor occupancy in rats treated with PBS (n=9), rMOv18 IgE (n=13) and rMOv18 IgG2b 
(n=9). (E) Correlation of within-tumor CD68+ macrophage density with survival of nude 
mice with intraperitoneal human ovarian carcinoma xenografts, treated with human PBMC 
and hMOv18 IgE (n=13). (F) Inhibition of subcutaneous IGROV1 tumor growth in SCID 
mice treated with PBS (n=4), hMOv18 IgE (n=4), monocyte-enriched effector cells (n=5), or 
monocyte-enriched effector cells plus hMOv18 IgE (n=5).
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Figure 4. Macrophages infiltrating tumors in IgE-treated rats are differentially-polarized.
(A) Single cell suspensions, isolated from lungs of rats inoculated with CC531tFR tumor 
cells 26 days previously, were stained with anti-CD45 and anti-CD68 antibodies. Infiltrating 
CD68+ macrophages were identified following successive gating on FSChiSSClow-hi and 
CD45+ populations (Supplementary Fig. S3) and the percentage of CD68+ cells in the 
CD45+ populations calculated (right panel). (B, C) Percentages of lung CD68+ 
macrophages expressing CD80, CD163, TNFα and IL-10. (3 independent experiments for 
Figs. A-C). (D) Percentages of single- and double-positive (TNFα+/IL-10+) cells within the 
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infiltrating CD68+ macrophage populations (n=3). (E) Cytokine/chemokine production 
measured in BAL fluid from tumor-bearing rats given rMOv18 IgE, rMOv18 IgG2b, or PBS 
(n=3 per group). (F) For selected analytes, fold change values represent mean fluorescence 
intensity (MFI) for each replicate within the treatment (IgE or IgG) groups, divided by that 
of the PBS group. Results represent 2 independent experiments.
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Figure 5. IgE cross-linked on monocytes triggers TNFα, which stimulates MCP-1.
(A) Comparative real-time PCR analysis of TNFα expression by U937 monocytes (left) or 
FRα+ human ovarian carcinoma IGROV1 tumor cells (right) following cross-linking of 
human IgEs and IgGs of different antigen specificities by polyclonal antibodies for 1 hour 
(n=4). (B, C) Effects of TNFα, IL-4 and IL-10 (20ng/mL) stimulation on relative mRNA 
expression and secretion of MCP-1 by U937 monocytes (B; 10-hour stimulation), human 
primary monocytes (B; 5-hour stimulation) and human ovarian carcinoma IGROV1, SKOV3 
and TOV21G, human breast carcinoma SKBR3, and human melanoma A375 tumor cells (C; 
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10-hour stimulation). (D) Quantitation of human primary monocytes (top left) or THP-1 
human monocytic cells, (bottom left) (representative images, right) migrating through a 
trans-well membrane in response to increasing MCP-1 concentrations (n=3).
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Figure 6. TNFα and MCP-1 are involved in IgE-mediated tumor killing and may be associated 
with better patient survival.
(A) hMOv18 IgE effects significantly-elevated killing of human ovarian carcinoma IGROV1 
cells by human U937 monocytes and primary monocytes in vitro, compared with non-
specific anti-NIP IgE controls (n=3). (B) Concentrations of cytokines/chemokines secreted 
in cultures of human primary monocytes incubated with IGROV1 cells and hMOv18 IgE, 
control antibody NIP IgE or no antibody. (C) MCP-1 secreted in cultures of U937 
monocytes incubated with IGROV1 cells and hMOv18 IgE was reduced when cells were 
incubated with blocking antibodies against the human TNFα receptors I and II prior to 
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incubating with hMOv18 IgE (representative of two independent experiments). (D) MCP-1 
mRNA expression by IGROV1 cells was elevated following co-incubation with U937 
monocytes and hMOv18 IgE compared to controls (left), and reduced MCP-1 expression 
detected when IGROV1 cells were incubated with blocking antibodies against the human 
TNFα receptors I and II prior to treatment with hMOv18 IgE (right). (E) Kaplan-Meier 
curves showing higher TNFα/MCP-1, TNFα/MCP-1/IL-10, TNFα/MCP-1/IL-10+CD68, 
FcεRIα or CD23 expression in 1582 ovarian cancers is significantly associated with 
improved 5-year overall survival. Ovarian tumor CD68 expression alone does not correlate 
with patient outcome. (F) Model summarizing a proposed mechanism of MOv18 IgE 
immunotherapy. (1) A TNFα/MCP-1 axis promotes potent recruitment of further 
macrophages into tumors, (2) resulting in enhanced tumor cell-macrophage interactions and 
subsequent tumor cell death.
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Figure 7. MOv18 IgE triggers ADCC of different FRα-expressing tumor cell lines by human 
effector cells from patients with ovarian cancer
(A) Paraffin-embedded sections of tumors from patients with ovarian cancer were stained to 
detect patients with FRα-positive (n=3) and FRα-negative (n=1) tumors. (B, C) ADCC/
ADCP of FRα-expressing human ovarian carcinoma IGROV1 cells by hMOv18 IgE-primed 
PBMCs from patients (B) with FRα-positive (n=3), FRα-negative (n=1) and FRα-status 
unknown (n=2) tumors and from healthy volunteers (n=2) (C). (D) hMOv18 IgE effects 
significantly-elevated killing of FRα-bright human ovarian carcinoma IGROV1 (n=3) and 
SKOV3 (n=3), and rat colon adenocarcinoma CC531tFR (n=2) tumor cells by monocytic 
cells, compared with non-specific anti-NIP IgE. Minimal killing of FRα-dim human ovarian 
carcinoma TOV21G (n=3) and human breast carcinoma SKBR3 (n=2) tumor cells by 
hMOv18 IgE was detected.
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